adenosine diphosphate has been researched along with Triple Negative Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ai, Y; Huang, J; Li, W; Li, Z; Wang, G; Yuan, J; Zan, X | 1 |
| Li, H; Li, S; Ouyang, Q; Shao, B; Tong, Z; Wang, Y; Xu, G; Zhang, Q | 1 |
1 trial(s) available for adenosine diphosphate and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Topics: Adenosine Diphosphate; Alanine Transaminase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; gamma-Glutamyltransferase; Humans; Immune Checkpoint Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Ribose; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
1 other study(ies) available for adenosine diphosphate and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Circ-CSNK1G1 promotes cell proliferation, migration, invasion and glycolysis metabolism during triple-negative breast cancer progression by modulating the miR-28-5p/LDHA pathway.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cell Line, Tumor; Cell Proliferation; Glucose; Glycolysis; Humans; L-Lactate Dehydrogenase; Mice; Mice, Nude; MicroRNAs; RNA, Circular; RNA, Messenger; Triple Negative Breast Neoplasms | 2022 |